LifeVantage Corp (NASDAQ:LFVN) Sees Large Increase in Short Interest
LifeVantage Corp (NASDAQ:LFVN) was the recipient of a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 965,300 shares, an increase of 31.8% from the September 30th total of 732,600 shares. Approximately 7.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 99,800 shares, the short-interest ratio is currently 9.7 days.
Hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC boosted its stake in shares of LifeVantage by 1.7% during the second quarter. Renaissance Technologies LLC now owns 1,123,748 shares of the company’s stock valued at $14,586,000 after purchasing an additional 18,343 shares during the period. BlackRock Inc. boosted its stake in shares of LifeVantage by 237.4% during the second quarter. BlackRock Inc. now owns 891,174 shares of the company’s stock valued at $11,568,000 after purchasing an additional 627,070 shares during the period. Vanguard Group Inc. boosted its stake in shares of LifeVantage by 4.8% during the second quarter. Vanguard Group Inc. now owns 665,728 shares of the company’s stock valued at $8,641,000 after purchasing an additional 30,342 shares during the period. Acadian Asset Management LLC boosted its stake in shares of LifeVantage by 14.7% during the second quarter. Acadian Asset Management LLC now owns 418,294 shares of the company’s stock valued at $5,430,000 after purchasing an additional 53,545 shares during the period. Finally, Jacobs Levy Equity Management Inc. boosted its stake in shares of LifeVantage by 214.7% during the second quarter. Jacobs Levy Equity Management Inc. now owns 117,545 shares of the company’s stock valued at $1,526,000 after purchasing an additional 80,199 shares during the period. Institutional investors own 41.45% of the company’s stock.
Separately, ValuEngine upgraded LifeVantage from a “strong sell” rating to a “sell” rating in a research report on Tuesday, October 29th.
LifeVantage (NASDAQ:LFVN) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $0.13 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.12 by $0.01. The company had revenue of $56.23 million for the quarter. LifeVantage had a net margin of 3.65% and a return on equity of 38.13%. On average, research analysts predict that LifeVantage will post 0.67 EPS for the current fiscal year.
LifeVantage Corporation engages in the identification, research, development, and distribution of nutraceutical dietary supplements and skin care products. The company offers Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skin care product; Axio, a line of energy drink mixes; Omega+, a fish oil dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and Vitamin D3; and PhysIQ, a weight management system, as well as Petandim for Dogs, a companion pet supplement formulated to treat oxidative stress in dogs.
Featured Story: Book Value Per Share – BVPS
Receive News & Ratings for LifeVantage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeVantage and related companies with MarketBeat.com's FREE daily email newsletter.